NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2016.

Cover of GeneReviews®

GeneReviews® [Internet].

Show details

Long QT Syndrome

, PhD and , PhD, MD.

Author Information
, PhD
Department of Clinical Genetics
Academic Medical Center
University of Amsterdam
Amsterdam, The Netherlands
, PhD, MD
Department of Clinical Genetics
Academic Medical Center
University of Amsterdam
Amsterdam, The Netherlands

Initial Posting: ; Last Update: June 18, 2015.

Summary

Clinical characteristics.

Long QT syndrome (LQTS) is a cardiac electrophysiologic disorder, characterized by QT prolongation and T-wave abnormalities on the ECG and the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing a syncopal event, the most common symptom in individuals with LQTS. Syncope typically occurs during exercise and high emotions, less frequently at rest or during sleep, and usually without warning. In some instances, TdP degenerates to ventricular fibrillation and causes aborted cardiac arrest (if the individual is defibrillated) or sudden death. Approximately 50% of individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms, usually one to a few syncopal spells. While cardiac events may occur from infancy through middle age, they are most common from the pre-teen years through the 20s. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia. In addition to the prolonged QT interval, associations include muscle weakness and facial dysmorphism in Andersen-Tawil syndrome (LQTS type 7), hand/foot, facial, and neurodevelopmental features in Timothy syndrome (LQTS type 8) and profound sensorineural hearing loss in Jervell and Lange-Nielson syndrome.

Diagnosis/testing.

Diagnosis of LQTS is established by prolongation of the QTc interval in the absence of specific conditions known to lengthen it (for example, QT-prolonging drugs) and/or by molecular genetic testing that identifies a diagnostic change (or changes) in one or more of the 15 genes known to be associated with LQTS, of which KCNQ1 (locus name LQT1), KCNH2 (LQT2) and SCN5A (LQT3) are the most common. Other, less frequently involved genes are ANK2 (LQT4), KCNE1 (LQT5), KCNE2 (LQT6), KCNJ2 (LQT7), CACNA1C (LQT8), CAV3 (LQT9), SCN4B (LQT10), AKAP9 (LQT11), SNTA1 (LQT12), KCNJ5 (LQT13), CALM1 (LQT14), and CALM2 (LQT15). Approximately 20% of families meeting clinical diagnostic criteria for LQTS do not have detectable pathogenic variants in one of the above genes. LQTS associated with biallelic pathogenic variants or heterozygosity for pathogenic variants in two different genes (i.e., digenic pathogenic variants) is generally associated with a more severe phenotype with longer QTc interval and a higher incidence of cardiac events.

Management.

Treatment of manifestations: Beta-blocker medication is the primary treatment for LQTS; possible implantable cardioverter-defibrillators (ICD) and/or left cardiac sympathetic denervation (LCSD) for those with beta-blocker-resistant symptoms, inability to take beta blockers, and/or history of cardiac arrest. Sodium channel blockers can be useful as additional pharmacologic therapy for patients with a QTc interval >500 ms.

Prevention of primary manifestations: Beta blockers are clinically indicated in all asymptomatic individuals meeting diagnostic criteria, including those who have a pathogenic variant on molecular testing and a normal QTc interval. In general, ICD implantation is not indicated for individuals with LQTS who are asymptomatic and who have not been tried on beta blocker therapy. Prophylactic ICD therapy can be considered for individuals with LQTS who are asymptomatic but suspected to be at very high risk (e.g., those with ≥2 pathogenic variants on molecular testing).

Surveillance: Regular assessment of beta-blocker dose for efficacy and adverse effects in all individuals with LQTS, especially children during rapid growth; regular periodic evaluations of ICDs for inappropriate shocks and pocket or lead complications.

Agents/circumstances to avoid: Drugs that cause further prolongation of the QT interval or provoke torsade de pointes; competitive sports/activities associated with intense physical activity and/or emotional stress for most individuals.

Evaluation of relatives at risk: Presymptomatic diagnosis and treatment is warranted in relatives at risk to prevent syncope and sudden death.

Other: For some individuals, availability of automatic external defibrillators at home, at school, and in play areas.

Genetic counseling.

LQTS is typically inherited in an autosomal dominant manner. An exception is LQTS associated with sensorineural deafness (known as Jervell and Lange-Nielsen syndrome), which is inherited in an autosomal recessive manner. Most individuals diagnosed with LQTS have an affected parent. The proportion of LQTS caused by a de novo pathogenic variant is small. Each child of an individual with autosomal dominant LQTS has a 50% risk of inheriting the pathogenic variant. Penetrance of the disorder may vary. Prenatal testing for pregnancies at increased risk and preimplantation genetic diagnosis are possible once the pathogenic variant(s) have been identified in the family.

Diagnosis

Suggestive Findings

Long QT syndrome (LQTS) should be suspected in individuals on the basis of ECG characteristics, clinical presentation, and family history.

ECG evaluation

Corrected QT (QTc) values on resting ECG. The QTc on resting ECG is neither completely sensitive nor specific for the diagnosis of LQTS. Approximately 25% of individuals with LQTS confirmed by the identification of a pathogenic variant in a LQTS-associated gene may have a normal range QTc (concealed LQTS) [Goldenberg et al 2011]. Also, there are several other factors that can lengthen the QTc interval :

  • QT-prolonging drugs
  • Hypokalemia
  • Certain neurologic conditions including subarachnoid bleed
  • Structural heart disease

The following tests are helpful for further evaluation of individuals with "uncertain" QTc values on resting ECG:

Clinical history. A personal history of syncope, aborted cardiac arrest, or sudden death in a child or young adult may lead to suspicion of LQTS. The syncope is typically precipitous and without warning, thus differing from the common vasovagal and orthostatic forms of syncope in which presyncope and other warning symptoms occur. Absence of aura, incontinence, and postictal findings help differentiate LQTS-associated syncope from seizures.

Family history. A family history of syncope, aborted cardiac arrest, or sudden death in a child or young adult and consistent with autosomal dominant inheritance or autosomal recessive inheritance supports the diagnosis of LQTS.

Establishing the Diagnosis

Schwartz et al [1993] proposed a scoring system to diagnose LQTS on a clinical basis; it was updated by Schwartz & Crotti [2011]. Points are assigned to various criteria (see Table 1).

Table 1.

Scoring System for Clinical Diagnosis of Long QT Syndrome

FindingsPoints
ECG 1QTc 2≥480 ms3
=460-479 ms2
=450-459 ms (in males)1
≥480 ms during 4th minute of recovery from exercise stress test1
Torsade de pointes 32
T wave alternans1
Notched T wave in 3 leads1
Low heart rate for age 40.5
Clinical
history
Syncope 3With stress2
Without stress1
Family
history
Family member(s) with definite LQTS 51
Unexplained sudden cardiac death before age 30 years among immediate family 50.5
Total score

Scoring:

≤1.0 point = low probability of LQTS

1.5-3.0 points = intermediate probability of LQTS

≥3.5 points = high probability of LQTS

Footnotes:

1.

In the absence of medications or disorders known to affect these electrocardiographic features

2.

QTc (corrected QT) calculated by Bazett’s formula where QTc = QT/√RR

3.

Mutually exclusive

4.

Resting heart rate <2nd percentile for age

5.

The same family member cannot be counted for both criteria.

The diagnosis of LQTS is established in a proband with one or more of the following [Priori et al 2013]:

  • A risk score of ≥3.5 (see Table 1) in the absence of a secondary cause for QT prolongation
  • The presence of a corrected QT interval ≥500 ms in repeated ECGs in the absence of a secondary cause for QT prolongation
  • The identification of a pathogenic variant in one of the 15 genes in which mutation causes LQTS

Molecular testing approaches may include:

  • Single-gene molecular genetic testing based on the individual’s phenotype (T-wave pattern and triggers of syncope), which has been shown to predict the genotype [Zhang et al 2000, Van Langen et al 2003] (see Table 3);
    Note: Pathogenic variants in KCNQ1, KCNH2, and SCN5A represent the most common causes of LQTS, accounting for 60%-75% of cases (see Table 2a). Pathogenic variants in other LQTS-associated genes are rarely found (see Table 2b).
  • Use of a multi-gene panel that includes all LQTS-associated genes and other genes of interest (see Differential Diagnosis).
    Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.

In either approach, sequence analysis is performed first; it may be followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found.

Note: In about 4%-10% of individuals with LQTS, two pathogenic variants are found (digenic/biallelic inheritance). These individuals have a more severe phenotype compared to those with one pathogenic variation with a longer QT interval, a younger age of onset of events, and a higher risk of events [Schwartz et al 2003, Westenskow et al 2004, Tester et al 2005, Itoh et al 2010]. Although there is considerable overlap in phenotypic characteristics between those with monogenic and digenic/biallelic pathogenic variants, one could consider sequencing of additional genes in cases with an extreme phenotype.

Table 2a.

Genes Mutated in >1% of Individuals with Long QT Syndrome (LQTS)

Gene 1Disease Name% of LQTS Attributed to Mutation of This Gene 2Proportion of Reported Pathogenic Variants 3 Detected by Test Method
Sequence analysis 4Gene-targeted deletion/duplication analysis 5
KCNQ1LQTS type 1 630%-35%97%-98%2%-3% 7
KCNH2LQTS type 225%-30%97%-98%
SCN5ALQTS type 35%-10%All variants reported to dateNone reported 8
1.
2.

Proportion of LQTS caused by a pathogenic variant in each gene is based on Splawski et al [2000], Napolitano et al [2005], Tester et al [2005], Kapa et al [2009], Kapplinger et al [2009].

3.

See Molecular Genetics for information on pathogenic allelic variants detected.

4.

Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.

5.

Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.

6.

Biallelic pathogenic variants in KCNQ1 are associated with Jervell and Lange-Nielsen syndrome.

7.

Deletions or duplications involving KCNQ1 or KCNH2 have been shown to be causal for LQTS in ~3% of cases [Barc et al 2011].

8.

The pathogenic variants in SCN5A that cause LQTS are due to pathogenic gain-of-function variants (loss-of-function variants of SCN5A cause Brugada syndrome). Therefore, it is highly unlikely that large deletions or duplications in SCN5A will be identified as a cause of LQTS.

Table 2b.

Genes Mutated in ≤1% of Individuals with Long QT Syndrome (LQTS)

Gene 1Disease NameComment
ANK2LQTS type 4<1%
KCNE1LQTS type 5 2<1%
KCNE2LQTS type 6<1%
KCNJ2LQTS type 7 3<1%
CACNA1CLQTS type 8 4<1%
CAV3LQTS type 9<1%
SCN4BLQTS type 10Rare (2 cases)
AKAP9LQTS type 11Rare (1 case)
SNTA1LQTS type 12Rare (3 cases)
KCNJ5LQTS type 13Rare (2 cases)
CALM1LQTS type 14<1%
CALM2LQTS type 15<1%
1.
2.

Biallelic pathogenic variants in KCNE1 are associated with Jervell and Lange-Nielsen syndrome.

3.

LQTS type 7 is also referred to as Andersen-Tawil syndrome.

4.

LQTS type 8 is also referred to as Timothy syndrome.

Note: Approximately 20% of families with a clinically firm diagnosis of LQTS do not have a detectable pathogenic variant in one of the fifteen genes (KCNQ1, KCNH2, SCN5A, ANK2, KCNE1, KCNE2, CAV3, KCNJ2, CACNA1C, SCN4B, AKAP9, SNTA1, KCNJ5, CALM1, and CALM2) known to be associated with LQTS, suggesting that pathogenic variants in other genes can also cause LQTS and/or that current test methods do not detect all pathogenic variants in the known genes.

Clinical Characteristics

Clinical Description

Long QT syndrome (LQTS) is characterized by QT prolongation and T-wave abnormalities on ECG that are associated with tachyarrhythmias, typically the ventricular tachycardia torsade de pointes (TdP). TdP is usually self-terminating, thus causing syncope, the most common symptom in individuals with LQTS. Syncope is typically precipitous and without warning. In some instances, TdP degenerates to ventricular fibrillation and aborted cardiac arrest (if the individual is defibrillated) or sudden death.

Approximately 50% or fewer of untreated individuals with a pathogenic variant in one of the fifteen genes (see Table 2a, Table 2b) associated with LQTS have symptoms [Vincent et al 1992, Zareba et al 1998]. The number of syncopal events in symptomatic individuals ranges from one to hundreds, averaging just a few.

Pathogenic variants in KCNQ1, KCNH2, and SCN5A account for the vast majority of cases of LQTS and distinct genotype-phenotype correlations have been reported (see Table 3). Three clinical phenotypes are recognized in individuals with pathogenic variants in these genes.

QTc range is similar across phenotypes (~400-600+ msec). The average QTc values are similar for the LQTS type 1 and LQTS type 2 phenotypes and somewhat longer for the LQTS type 3 phenotype.

T-wave patterns characteristic for the LQTS type 1, 2, and 3 phenotypes have been reported and can assist in directing molecular genetic testing strategies to identify the gene involved [Zhang et al 2000].

Cardiac events often have genotype-specific triggers [Schwartz et al 2001]. In the LQTS type 1 phenotype symptoms are mostly triggered by exercise while in the LQTS type 2 phenotype emotional stress and auditory stimuli trigger events. In the LQTS type 3 phenotype symptoms mostly occur during sleep.

Table 3.

Genotype-Phenotype Correlations

PhenotypeGeneAverage QTcST-T-Wave MorphologyIncidence of Cardiac EventsCardiac Event TriggerSudden Death Risk
LQTS type 1KCNQ1480 msecBroad-base T-wave63%Exercise, emotion6%-8%
LQTS type 2KCNH2Bifid T-waves46%Exercise, emotion, sleep6%-8%
LQTS type 3SCN5A~490 msecLong ST, small T18%Sleep6%-8%

Age-related risk. Cardiac events may occur from infancy through middle age but are most common from the pre-teen years through the 20s, with the risk generally diminishing throughout that time period. The usual age range of events differs somewhat for each genotype. Cardiac events are uncommon after age 40 years; when present, they are often triggered by administration of a QT-prolonging drug or hypokalemia or are associated with the LQTS type 3 phenotype.

Overall risk of cardiac events. Of individuals who die of complications of LQTS, death is the first sign of the disorder in an estimated 10%-15%. It is difficult to establish numbers on the risk of cardiac events in LQTS since most individuals are treated. Studies from the long QT registry including patients, individuals with a pathogenic variant (mostly treated) and also relatives who died suddenly show a cumulative mortality before the age of 40 years of 6%-8% in the LQTS type 1, type 2, and type 3 phenotypes. In individuals between 0 to 18 years, those with a LQTS type 1, type 2, or type 3 phenotype had a cumulative mortality of 2%, 3%, and 7% respectively. From 19 to 40 years mortality rates were 5%, 7%, and 5% respectively [Zareba et al 1998, Goldenberg et al 2008]. Although syncopal events are most common in the LQTS type 1 phenotype (63%), followed by the LQTS type 2 phenotype (46%) and LQTS type 3 phenotype (18%), the incidence of death is similar in all three. A study using the family tree mortality rate method studied mortality in large families with LQTS, in times when disease was not known and individuals received no treatment, compared to the normal population. For the LQTS type 1 phenotype, severely increased mortality was shown throughout childhood (ages 1-19 years), for the type 2 phenotype, increased mortality between ages 15 and 39 years was seen, and in the type 3 phenotype, increased mortality between ages 15 and 19 years was seen [Nannenberg et al 2012].

Non-cardiac features. Some types of LQTS are associated with a phenotype extending beyond cardiac arrhythmia.

  • Andersen-Tawil syndrome (LQTS type 7) is associated with prolonged QT interval, muscle weakness, and facial dysmorphism.
  • Timothy syndrome (LQTS type 8) is characterized by prolonged QT interval and hand/foot, facial, and neurodevelopmental features.
  • Jervell and Lange-Nielson syndrome (JLNS), an LQTS disorder associated with biallelic pathogenic KCNQ1 or KCNE1 variants, is associated with profound sensorineural hearing loss.

Genotype-Phenotype Correlations

Long QT syndrome (LQTS) associated with biallelic pathogenic variants or heterozygosity for pathogenic variants in two different genes (i.e., digenic pathogenic variants) is generally associated with a more severe phenotype with longer QTc interval and a higher incidence of cardiac events [Schwartz et al 2003, Westenskow et al 2004, Tester et al 2005, Itoh et al 2010].

There are no specific genotype-phenotype correlations known other than as noted in Clinical Description.

Penetrance

LQTS exhibits reduced penetrance of the ECG changes and symptoms. Overall, approximately 25% of individuals with a pathogenic variant have a normal QTc (defined as <440 msec) on baseline ECG. The percentage of genetically affected individuals with a normal QTc was higher in the LQTS type 1 group (36%) than in the LQTS type 2 group (19%) or the type 3 group (10%) [Priori et al 2003, Goldenberg et al 2011].

As noted in Table 3, penetrance for symptoms is also reduced. At least 37% of individuals with the LQTS type 1 phenotype, 54% with the type 2 phenotype, and 82% with the type 3 phenotype remain asymptomatic.

Nomenclature

The term “Romano-Ward syndrome” refers to forms of long QT syndrome with a purely cardiac phenotype, inherited in an autosomal dominant manner (LQTS types 1-3, type 5, type 6, and types 9-15).

Prevalence

The prevalence of LQTS has been estimated at 1:2000 [Schwartz et al 2009].

LQTS has been identified in all ethnic groups.

Differential Diagnosis

Other causes of QTc interval prolongation to be considered:

  • QT-prolonging drugs
  • Hypokalemia
  • Certain neurologic conditions including subarachnoid bleed
  • Structural heart disease

Other causes of syncope or sudden death to be considered in children and young adults:

  • Sudden infant death syndrome (SIDS), commonly defined as unexpected sudden death within the first year of life. Death during the first year of life in families with LQTS appears to be rare, yet a percent of infants dying of SIDS have been shown to have pathogenic variants in one of the LQTS-related genes [Ackerman et al 2001, Schwartz et al 2001, Arnestad et al 2007]. While it seems probable that these pathogenic variants were the cause of the SIDS, the association is uncertain, and the frequency of pathogenic variants in SIDS cases has been questioned [Wedekind et al 2006].
  • Vasovagal (neurally mediated) syncope, orthostatic hypotension
  • Seizures
  • Familial ventricular fibrillation
  • Subtle cardiomyopathies (HCM, DCM, ARVC)
  • Anomalous coronary artery
  • Drug-induced QT prolongation (see drugs at CredibleMeds®)

Management

Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with LQTS, the main focus in the management of individuals with LQTS is to identify the subset of individuals at high risk for cardiac events. For this risk stratification the following evaluations are recommended:

  • ECG evaluation. Individuals with a QTc interval >500 ms are at higher risk for an event; individuals with QTc interval >600 ms are at extremely high risk [Priori et al 2003, Goldenberg et al 2008] Overt T-wave alternans, especially when present despite proper beta-blocker therapy, is also associated with a higher risk of cardiac events [Priori et al 2013]. Individuals with a pathogenic variant who have a normal QTc interval are at low risk [Priori et al 2013].
  • Medical history. Individuals with syncope or cardiac arrest in the first year of life [Schwartz et al 2009, Spazzolini et al 2009] or younger than age seven years [Priori et al 2004] are at higher risk. These individuals may not be fully protected by pharmacologic treatment. Individuals with arrhythmic events while on proper pharmacologic treatment are also at higher risk [Priori et al 2013]. Asymptomatic individuals with pathogenic variants or individuals with prolonged QT intervals who have been asymptomatic at a young age (age <40 years) are at low risk for events later in life, although females remain at risk after age 40 years [Locati et al 1998].
  • Medical genetics consultation

Treatment of Manifestations

All symptomatic persons should be treated (see Priori et al [2013]). Complete cessation of symptoms is the goal. Management is focused on the prevention of syncope, cardiac arrest, and sudden death through use of the following:

  • Beta blockers are the mainstay of therapy for LQTS, including asymptomatic individuals with prolonged QT intervals and individuals who have a pathogenic variant on molecular testing with a normal QTc interval [Priori et al 2004, Schwartz et al 2009]. Some individuals have symptoms despite the use of beta blockers [Moss et al 2000]. However, a majority of cardiac events that occur in individuals with LQTS type 1 phenotype “on beta-blockers” are not caused by failure of the medication, but in fact by failure to take the medication (non-compliance) and/or the administration of QT-prolonging drugs [Vincent et al 2009]. It is suspected that the same holds true for individuals with LQTS type 2, but that has not been systematically studied. It is therefore important that:
    • Inadequate beta blocker dosing is prevented by regular adjustments in growing children with evaluation of the efficacy of dose by assessment of the exercise ECG or ambulatory ECG;
    • Beta blockers are taken daily, and strategies are in place in case of missed doses;
    • QT-prolonging drugs (see Agents/Circumstances to Avoid) are not administered to persons with LQTS without careful consideration of risk versus benefit by the individual(s) and physician(s).
  • Implantable cardioverter-defibrillators (ICDs) are recommended in individuals with LQTS resuscitated from a cardiac arrest, although children with a LQTS type 1 phenotype with an arrest while not receiving beta blockers can be treated with beta blockers or with left cardiac sympathetic denervation [Alexander et al 2004, Vincent et al 2009, Jons et al 2010]. ICDs can be useful for those individuals with beta-blocker-resistant symptoms or a contraindication for beta blocker therapy (severe asthma) [Zareba et al 2003, Priori et al 2013].
  • Left cardiac sympathetic denervation (LCSD) is recommended for high-risk patients with LQTS in whom ICD therapy is refused or contraindicated and/or in whom beta blockers are either not effective, not tolerated, not accepted, or contraindicated [Schwartz et al 2004, Priori et al 2013]. LCSD can be useful in individuals who experience events while on therapy with beta blockers or ICD [Priori et al 2013].
  • Sodium channel blockers can be useful as additional pharmacological therapy for individuals with a LQTS type 3 phenotype with a QTc interval >500 ms in whom this additional compound is shown to shorten the QTc interval by >40 ms [Priori et al 2013].

Prevention of Primary Manifestations

Beta blockers. Beta blockers are clinically indicated in all asymptomatic individuals, including those who have a pathogenic variant on molecular testing with a normal QTc interval [Priori et al 2004, Schwartz et al 2009]. Males who have a pathogenic variant and who have been asymptomatic before 40 years are at low risk of cardiac events. In these individuals the necessity of beta-blockers can be discussed [Locati et al 1998].

ICD. In general, ICD implantation is not indicated for asymptomatic individuals with LQTS who have not been tried on beta blocker therapy. Prophylactic ICD therapy can be considered for asymptomatic individuals suspected to be at very high risk, such as asymptomatic individuals with two or more pathogenic variants on molecular testing [Priori et al 2013]. LQTS-related sudden death in a close relative is not an indication for an ICD in surviving relatives [Kaufman et al 2008].

Prevention of Secondary Complications

Examine the past medical history for asthma, orthostatic hypotension, depression, and diabetes mellitus because these disorders may be exacerbated by treatment with beta blockers.

Although the incidence of arrhythmias during elective interventions such as surgery, endoscopies, childbirth, or dental work is low, it is prudent to monitor the ECG during such interventions and to alert the appropriate medical personnel in case intervention is needed.

Surveillance

Beta-blocker dose should be regularly assessed for efficacy and adverse effects; doses should be altered as needed. Dose adjustment including efficacy testing is especially important in growing children.

Individuals with an ICD implanted should have regular, periodic evaluations of ICDs for inappropriate shocks and pocket or lead complications.

Agents/Circumstances to Avoid

Drugs that cause further prolongation of the QT interval or provoke torsade de pointes should be avoided for all individuals with LQTS. See CredibleMeds® (free registration required) for a complete and updated list. Epinephrine given as part of local anesthetics can trigger arrhythmias and is best avoided.

Since electrolyte imbalances may also lengthen the QTc interval, identification and correction of electrolyte abnormalities is important. These imbalances can occur as a result of diarrhea, vomiting, metabolic conditions, and imbalanced diets for weight loss.

Lifestyle modifications are advised based on genotype. For individuals with LQTS type 1 phenotype avoidance of strenuous exercise – especially swimming without supervision – is advised. In individuals with LQTS type 2 phenotype reduction in exposure to loud noises such as alarm clocks and phone ringing is advised. In individuals at high risk for cardiac events or with exercise-induced symptoms competitive sport should be avoided [Priori et al 2013]. For some individuals participation in competitive sports may be safe. It is therefore recommended that all individuals with LQTS who wish to engage in competitive sports have their risk evaluated by a clinical expert [Johnson & Ackerman 2012, Priori et al 2013].

Evaluation of Relatives at Risk

Presymptomatic diagnosis of at-risk relatives followed by treatment is necessary to prevent syncope and sudden death in those individuals who have inherited the pathogenic variant and/or have ECG findings consistent with LQTS. At-risk family members should be alerted to their risk and the need to be evaluated.

Relatives at high potential risk for LQTS who require further testing include members of a family:

  • That has documented LQTS;
  • In which evaluation for LQTS has not been performed.

Presymptomatic diagnosis for at-risk asymptomatic family members can be performed by one or both of the following:

  • Molecular genetic testing if the pathogenic variant in the family is known
  • If the pathogenic variant is not known or if genetic testing is not possible, QTc analysis on resting and in case of normal QTc also QTc analysis on exercise ECGs
    Note: The diagnostic accuracy by QTc analysis is considerably improved by evaluation of the exercise ECG QTc intervals, in addition to the resting ECG, using the QTc values listed in Table 1.

Relatives at low potential risk who do not require further testing include members of a family in which the connecting ancestor:

  • Has a low probability of LQTS based on QTc interval (see Table 1) and has not experienced LQTS-type events; or
  • Has a normal QTc interval and no evidence of a pathogenic variant in one of the genes known to cause LQTS; or
  • Does not have the family-specific pathogenic variant, if known.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

Pregnancy Management

The post-partum period is associated with increased risk for a cardiac event, especially in individuals with the LQTS type 2 phenotype. Beta blocker treatment was associated with a reduction of events in this nine-month time period after delivery [Seth et al 2007].

Therapies Under Investigation

Gene-specific therapies (mostly for LQTS type 3 phenotype) have been investigated, especially in individuals with cardiac events despite beta blocker, ICD, or LCSD therapy. Examples are mexiletine [Schwartz et al 1995], flecainide [Moss et al 2005], and ranolazine [Moss et al 2008]. Follow-up experience with these drugs is still limited.

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.

Other

Most affected individuals live normal lifestyles. Education of adult individuals and the parents of affected children, especially about beta blocker compliance, is an important aspect of management.

Genetic Counseling

Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.

Mode of Inheritance

Long QT syndrome (LQTS) is typically inherited in an autosomal dominant manner.

LQTS with extracardiac signs can be inherited in an autosomal dominant or autosomal recessive manner. Timothy syndrome and Andersen-Tawil syndrome are inherited in an autosomal dominant manner. Jervell and Lange-Nielsen syndrome is inherited in an autosomal recessive manner (see Jervell and Lange-Nielsen Syndrome, Genetic Counseling for discussion of autosomal recessive inheritance and genetic counseling for this disorder).

Risk to Family Members — Autosomal Dominant Inheritance

Parents of a proband

  • The majority of individuals diagnosed with LQTS have inherited a pathogenic variant from a parent.
  • A proband with LQTS may have the disorder as the result of a de novo pathogenic variant. The proportion of cases caused by de novo pathogenic variants is small.
  • If the pathogenic variant identified in the proband cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or a de novo pathogenic variant in the proband.
  • If the parent from whom the proband inherited a pathogenic variant cannot be determined on the basis of clinical and family history, molecular genetic testing should be offered to both parents to identify which one has the pathogenic variant identified in the proband.
  • The family history of some individuals diagnosed with LQTS may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or reduced penetrance. Therefore, an apparently negative family history cannot be confirmed unless appropriate clinical evaluation and/or molecular genetic testing has been performed on the parents of the proband (see Management, Evaluation of Relatives at Risk).

Note: Biallelic and digenic pathogenic variants been described (see Genotype-Phenotype Correlations). If an individual with LQTS has biallelic or digenic pathogenic variants, the possibility that both parents have pathogenic variants should be considered.

Sibs of a proband

  • The risk to the sibs of the proband depends on the genetic status of the proband's parents.
  • If a parent of the proband has a pathogenic variant, the risk to the sibs of inheriting the pathogenic variant is 50%.
  • When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.
  • When the parents are clinically unaffected and the pathogenic variant is not known in the family, the risk to the sibs of a proband is increased, but cannot be accurately estimated.

Offspring of a proband. Each child of an individual with LQTS has a 50% chance of inheriting the pathogenic variant.

Other family members of a proband

  • The risk to other family members depends on the genetic status of the proband's parents.
  • If a parent is clinically affected or has a pathogenic variant, his or her family members are at risk.

Specific risk issues. With the reduced penetrance of symptoms in individuals with LQTS, careful ECG evaluation, including exercise ECG, is often necessary to identify affected family members accurately. The absence of a family history of sudden death is common and does not negate the diagnosis or preclude the possibility of sudden death in relatives.

Related Genetic Counseling Issues

Testing of at-risk asymptomatic adults and children. Testing of at-risk asymptomatic adults for LQTS is possible using the techniques described in Diagnosis, Establishing the Diagnosis. Such testing is not useful in predicting age of onset, severity, type of symptoms, or rate of progression in asymptomatic individuals. To facilitate the use of morbidity- and mortality-reducing interventions, presymptomatic testing of all at-risk family members, especially including individuals younger than age 18 years because risk of cardiac events is greatest in childhood, should be considered (see Management, Evaluation of Relatives at Risk). When testing at-risk individuals for LQTS, an affected family member should be tested first to identify the pathogenic variant in the family. If no pathogenic variant is identified in an affected family member (the case in ~20% of families with LQTS) [Ackerman et al 2011], at-risk relatives should undergo careful clinical examination.

Considerations in families with an apparent de novo pathogenic variant. When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has a de novo pathogenic variant. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.

Family planning

  • The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.
  • It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.

DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

Prenatal Testing

If a pathogenic variant has been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory that offers either testing of the gene of interest or custom prenatal testing.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.

Preimplantation genetic diagnosis (PGD) may be an option for some families in which the pathogenic variant has been identified.

Resources

GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click here.

  • National Library of Medicine Genetics Home Reference
  • Canadian SADS Foundation
    9-6975 Meadowvale Town Centre Circle
    Suite 314
    Mississauga Ontario L5N 2V7
    Canada
    Phone: 877-525-5995 (toll-free); 905-826-6303
    Fax: 905-826-9068
    Email: info@sads.ca
  • SADS Australia
    Victoria
    Australia
    Email: omeara.sads@live.com.au
  • Sudden Arrhythmia Death Syndromes (SADS) Foundation
    508 East South Temple
    Suite #202
    Salt Lake City UT 84102
    Phone: 800-786-7723 (toll-free); 801-531-0937
    Email: sads@sads.org
  • Long QT Syndrome (LQTS) Registry
    An ongoing research study with the goal of contributing to a better understanding of the genetics, natural history, and treatment of LQTS. Currently enrolling families in which a mutation has already been identified.
    University of Rochester Medical Center
    265 Crittenden Boulevard
    CU 420653
    Rochester NY 14642-0653
    Phone: 585-276-0016
    Fax: 585-273-5283

Molecular Genetics

Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. —ED.

Table A.

Long QT Syndrome: Genes and Databases

Locus NameGeneChromosome LocusProteinLocus SpecificHGMD
LQT1KCNQ111p15​.5-p15.4Potassium voltage-gated channel subfamily KQT member 1KCNQ1 @ LOVD
KCNQ1 @ ZAC-GGM
Deafness Gene Mutation Database (KCNQ1)
Gene Connection for the Heart - KCNQ1 (KVLQT1)
KCNQ1
LQT2KCNH27q36​.1Potassium voltage-gated channel subfamily H member 2KCNH2 @ ZAC-GGM
Gene Connection for the Heart - KCNH2(HERG)
KCNH2 database
KCNH2
LQT3SCN5A3p22​.2Sodium channel protein type 5 subunit alphaSCN5A @ LOVD
SCN5A @ ZAC-GGM
Gene Connection for the Heart - SCN5A (LQT3)
SCN5A
LQT4ANK24q25-q26Ankyrin-2ANK2 @ ZAC-GGM
Gene Connection for the Heart - Ankyrin mutations database
ANK2 database
ANK2
LQT5KCNE121q22​.12Potassium voltage-gated channel subfamily E member 1KCNE1 @ LOVD
KCNE1 @ ZAC-GGM
Deafness Gene Mutation Database (KCNE1)
Gene Connection for the Heart - Long QT syndrome type 5 mutation database (KCNE1)
CCHMC - Human Genetics Mutation Database (KCNE1)
KCNE1
LQT6KCNE221q22​.11Potassium voltage-gated channel subfamily E member 2KCNE2 @ ZAC-GGM
Gene Connection for the Heart - Long QT syndrome type 6 mutation database
KCNE2 database
KCNE2
LQT7KCNJ217q24​.3Inward rectifier potassium channel 2KCNJ2 @ ZAC-GGM
Gene Connection for the Heart - KCNJ2
KCNJ2 database
KCNJ2
LQT8CACNA1C12p13​.33Voltage-dependent L-type calcium channel subunit alpha-1CCACNA1C @ ZAC-GGM
Gene Connection for the Heart - LQT8 (Timothy syndrome) database
CACNA1C database
CACNA1C
LQT9CAV33p25​.3Caveolin-3Gene Connection for the Heart - Long QT syndrome type 9 mutation database
Leiden Muscular Dystrophy pages (CAV3)
CAV3 @ ZAC-GGM
CAV3
LQT10SCN4B11q23​.3Sodium channel subunit beta-4SCN4B @ ZAC-GGM
SCN4B database
SCN4B
LQT11AKAP97q21​.2A-kinase anchor protein 9AKAP9 @ ZAC-GGM
AKAP9 database
AKAP9
LQT12SNTA120q11​.21Alpha-1-syntrophinSNTA1 @ ZAC-GGM
SNTA1 database
SNTA1
LQT13KCNJ511q24​.3G protein-activated inward rectifier potassium channel 4KCNJ5 databaseKCNJ5
LQT14CALM114q32​.11Calmodulin CALM1
LQT15CALM22p21Calmodulin CALM2

Data are compiled from the following standard references: gene from HGNC; chromosome locus, locus name, critical region, complementation group from OMIM; protein from UniProt. For a description of databases (Locus Specific, HGMD) to which links are provided, click here.

Table B.

OMIM Entries for Long QT Syndrome (View All in OMIM)

106410ANKYRIN 2; ANK2
114180CALMODULIN 1; CALM1
114182CALMODULIN 2; CALM2
114205CALCIUM CHANNEL, VOLTAGE-DEPENDENT, L TYPE, ALPHA-1C SUBUNIT; CACNA1C
152427POTASSIUM CHANNEL, VOLTAGE-GATED, SUBFAMILY H, MEMBER 2; KCNH2
170390ANDERSEN CARDIODYSRHYTHMIC PERIODIC PARALYSIS
176261POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 1; KCNE1
192500LONG QT SYNDROME 1; LQT1
600163SODIUM CHANNEL, VOLTAGE-GATED, TYPE V, ALPHA SUBUNIT; SCN5A
600681POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 2; KCNJ2
600734POTASSIUM CHANNEL, INWARDLY RECTIFYING, SUBFAMILY J, MEMBER 5; KCNJ5
600919CARDIAC ARRHYTHMIA, ANKYRIN-B-RELATED
601005TIMOTHY SYNDROME; TS
601017SYNTROPHIN, ALPHA-1; SNTA1
601253CAVEOLIN 3; CAV3
603796POTASSIUM CHANNEL, VOLTAGE-GATED, ISK-RELATED SUBFAMILY, MEMBER 2; KCNE2
603830LONG QT SYNDROME 3; LQT3
604001A-KINASE ANCHOR PROTEIN 9; AKAP9
607542POTASSIUM CHANNEL, VOLTAGE-GATED, KQT-LIKE SUBFAMILY, MEMBER 1; KCNQ1
608256SODIUM CHANNEL, VOLTAGE-GATED, TYPE IV, BETA SUBUNIT; SCN4B
611818LONG QT SYNDROME 9; LQT9
611819LONG QT SYNDROME 10; LQT10
611820LONG QT SYNDROME 11; LQT11
612955LONG QT SYNDROME 12; LQT12
613485LONG QT SYNDROME 13; LQT13
613688LONG QT SYNDROME 2; LQT2
613693LONG QT SYNDROME 6; LQT6
613695LONG QT SYNDROME 5; LQT5
616247LONG QT SYNDROME 14; LQT14
616249LONG QT SYNDROME 15; LQT15

Molecular Genetic Pathogenesis

The genes associated with LQTS encode for potassium or sodium cardiac ion channels or interacting proteins. Pathogenic variants in these genes cause abnormal ion channel function: a loss of function in the potassium channels and a gain of function in the sodium channel. This abnormal ion function results in prolongation of the cardiac action potential and susceptibility of the cardiac myocytes to early after depolarizations (EADs), which initiate the ventricular arrhythmia, torsade de pointes (TdP).

For a detailed summary of gene and protein information for the genes listed below, see Table A, Gene.

KCNQ1

Gene structure. KCNQ1 spans approximately 400 kb. The predominant isoform (isoform 1, refseq NM_000218.2) consists of 16 exons and produces a protein of 676 amino acids. Other isoforms, encoding a protein with an alternative N terminal domain (isoform 2) or non-coding transcripts exist.

Pathogenic allelic variants. More than 500 pathogenic variants of KCNQ1 have been reported, including pathogenic missense, nonsense, splice site, and frameshift variants as well as large multiexon deletions (see Note).

Normal gene product. The potassium voltage-gated channel subfamily KQT member 1 is the alpha subunit forming the slowly activating potassium delayed rectifier IKs [Keating & Sanguinetti 2001].

Abnormal gene product. IKs channel with reduced function

KCNH2

Gene structure. KCNH2 spans approximately 19 kb. The longest isoform consists of 16 exons and produces a protein of 1159 amino acids (NM_000238.3). Two shorter isoforms of KCNH2 exist.

Pathogenic allelic variants. More than 700 pathogenic variants have been reported, including pathogenic missense, nonsense, splice site and frameshift variants as well as large multiexon deletions (see Note).

Normal gene product. The potassium voltage-gated channel subfamily H member 2 is the alpha subunit forming the rapidly activating potassium delayed rectifier Ikr.

Abnormal gene product. IKr channel with reduced function

SCN5A

Gene structure. SCN5A consists of 28 exons, spans approximately 80 kb; it encodes a protein of 2016 amino acids (NM_198056.2). An isoform lacking amino acid Gln1077 exists.

Pathogenic allelic variants. More than 200 pathogenic variants are known; they include pathogenic missense variants and in-frame deletions or insertions.

Normal gene product. The sodium channel protein type V alpha subunit is the alpha subunit forming the cardiac sodium channel.

Abnormal gene product. Pathogenic gain-of-function variant resulting in a cardiac sodium channel with increased persistent inward current

ANK2

Gene structure. ANK2 consists of 46 exons spanning approximately 350 kb; it encodes a protein of 3957 amino acids (NM_001148.4). Alternative spliced variants exist.

Pathogenic allelic variants. More than 20 pathogenic variants in ANK2, associated with LQTS, have been described.

Normal gene product. Ankyrin 2, neuronal is required for targeting and stability of Na/Ca exchanger 1, Na/K ATPase, and InsP3 receptor in cardiomyocytes.

Abnormal gene product. Pathogenic loss-of-function variant resulting in disturbed coordination of multiple functionally related ion channels and transporters

KCNE1

Gene structure. KCNE1 consists of three exons spanning approximately 40 kb, it encodes a protein of 129 amino acids (NM_000219.3).

Pathogenic allelic variants. At least 36 pathogenic variants have been described, including pathogenic missense, nonsense, and frameshift variants (see Note).

Normal gene product. The potassium voltage-gated channel subfamily E member 1 is the beta subunit forming the slowly activating potassium delayed rectifier IKs. The two subunits encoded by KCNE1 and KCNQ1 coassemble to form the IKs channel.

Abnormal gene product. IKs channel with reduced function

KCNE2

Gene structure. KCNE2 consists of three exons spanning approximately 40 kb; it encodes a protein of 123 amino acids (NM_172201.1).

Pathogenic allelic variants. At least 20 pathogenic variants have been reported; they include missense and frameshift variants (see Molecular Genetic Pathogenesis).

Normal gene product. The potassium voltage-gated channel subfamily E member 2 is the beta subunit forming the rapidly activating potassium delayed rectifier IKr. The two subunits encoded by KCNH2 and KCNE2 coassemble to form the IKr channel.

Abnormal gene product. IKr channel with reduced function

KCNJ2

Gene structure. KCNJ2 consists of two exons spanning approximately 15 kb; it encodes a protein of 428 amino acids (NM_000891.2).

Pathogenic allelic variants. More than 70 pathogenic variants in KCNJ2 associated with long QT/Andersen-Tawil syndrome have been described.

Normal gene product. The potassium channel, inwardly rectifying subfamily J, member 2 is an inward-rectifier type potassium channel (Kir2.1).

Abnormal gene product. Dominant negative pathogenic variants resulting in decreased potassium currents

CACNA1C

Gene structure. CACNA1C consists of forty-seven exons spanning approximately 650 kb; it encodes a protein of 2138 amino acids (NM_000719.6). Multiple alternative spliced variants exist.

Pathogenic allelic variants. Only a few pathogenic variants in CACNA1C associated with long QT/Timothy syndrome have been described.

Normal gene product. The calcium channel, voltage-dependent, L type, alpha 1C subunit is the alpha-1 subunit of a cardiac voltage-dependent calcium channel .

Abnormal gene product. Pathogenic variants in exons 8 or 8A causing reduced channel inactivation, resulting in maintained depolarizing L-type calcium currents

CAV3

Gene structure. CAV3 consists of two exons spanning approximately 12 kb; it encodes a protein of 151 amino acids (NM_033337.2).

Pathogenic allelic variants. Five probable LQTS-causing missense variants in CAV3 have been described.

Normal gene product. The caveolin-3 protein is the major scaffolding protein present in caveolae in the heart.

Abnormal gene product. Persistent late sodium current

SCN4B

Gene structure. SCN4B consists of five exons spanning approximately 20 kb; it encodes a protein of 228 amino acids (NM_174934). A shorter isoform exists.

Pathogenic allelic variants. Two pathogenic missense variants in SCN4B have been associated with LQTS.

Normal gene product. The sodium channel protein type IV beta subunit is a beta subunit forming the cardiac sodium channel.

Abnormal gene product. Pathogenic loss-of-function variant resulting in a cardiac sodium channel with increased persistent inward current

AKAP9

Gene structure. AKAP9 consists of 50 exons and encodes a protein of 3907 amino acids (NM_005751.4). A shorter isoform exists.

Pathogenic allelic variants. One pathogenic missense variant in AKAP9 associated with LQTS has been described.

Normal gene product. The A kinase (prka) anchor protein (yotiao) 9 is involved in macromolecular complexes controlling phosphorylation of a number of proteins, including the Iks channel.

Abnormal gene product. Pathogenic loss-of-function variant resulting in an IKs channel with reduced function

SNTA1

Gene structure. SNTA1 consists of eight exons spanning approximately 35 kb; it encodes a protein of 505 amino acids (NM_003098.2).

Pathogenic allelic variants. Three pathogenic missense variants in SNTA1 associated with LQTS have been described.

Normal gene product. The alpha-1 syntrophin is a scaffolding protein involved in macromolecular complexes controlling the function of, among others, the cardiac sodium channel.

Abnormal gene product. Pathogenic loss-of-function variant resulting in a cardiac sodium channel with increased persistent inward current

KCNJ5

Gene structure. KCNJ5 consists of three exons spanning approximately 30 kb; it encodes a protein of 419 amino acids (NM_000890.3).

Pathogenic allelic variants. Two pathogenic missense variants in KCNJ5 associated with LQTS have been described.

Normal gene product. The potassium inwardly-rectifying channel, subfamily J, member 5 is a subunit of the cardiac inwardly rectifying potassium channel IKACh.

Abnormal gene product. Pathogenic loss-of-function variant resulting in an IKACh channel with reduced function

CALM1

Gene structure. CALM1 consists of six exons spanning approximately 11 kb; it encodes a protein of 149 amino acids (NM_006888.4).

Pathogenic allelic variants. Only a few pathogenic variants in CALM1 have been described.

Normal gene product. Calmodulin 1 is a calcium-modulated protein regulating L-type calcium channel function.

Abnormal gene product. Pathogenic variants in CALM1 result in several-fold reduction in calcium-binding affinity.

CALM2

Gene structure. CALM2 consists of six exons spanning approximately 16 kb; it encodes a protein of 149 amino acids (NM_001743.4).

Pathogenic allelic variants. Only a few pathogenic variants in CALM2 have been described.

Normal gene product. Calmodulin 2 is a calcium-modulated protein regulating L-type calcium channel function.

Abnormal gene product. Pathogenic variants in CALM2 result in several-fold reduction in calcium-binding affinity.

Note

More than 1400 pathogenic variants in the 15 LQTS-related genes have been reported and are listed in the various databases found in Table A. In general, approximately 70% of pathogenic variants reported are missense, 15% are frameshift, and in-frame deletions, nonsense, and splice site variants make up 3%-6% each. However, this distribution varies by gene. Radical pathogenic variants such as frameshift, nonsense, and splice site types are relatively more frequent in KCNQ1 and KCNH2 and are not present in SCN5A in individuals with LQTS (such pathogenic variants in SCN5A cause Brugada syndrome rather than LQTS).

References

Published Guidelines/Consensus Statements

  1. American College of Cardiology/American Heart Association Task Force, and the European Society of Cardiology/Committee for Practice Guidelines. Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Available online. 2006. Accessed 9-4-15. [PubMed: 16935866]
  2. Vincent GM. Role of DNA testing for diagnosis, management, and genetic screening in long QT syndrome, hypertrophic cardiomyopathy, and Marfan syndrome. Heart. 86:12-4. Available online. 2001. Accessed 9-4-15. [PMC free article: PMC1729812] [PubMed: 11410552]

Literature Cited

  1. Ackerman MJ, Khositseth A, Tester DJ, Hejlik JB, Shen WK, Porter CB. Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc. 2002;77:413–21. [PubMed: 12004990]
  2. Ackerman MJ, Priori SG, Willems S, Berul C, Brugada R, Calkins H, Camm AJ, Ellinor PT, Gollob M, Hamilton R, Hershberger RE, Judge DP, Le Marec H, McKenna WJ, Schulze-Bahr E, Semsarian C, Towbin JA, Watkins H, Wilde A, Wolpert C, Zipes DP. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Heart Rhythm. 2011;8:1308–39. [PubMed: 21787999]
  3. Ackerman MJ, Siu BL, Sturner WQ, Tester DJ, Valdivia CR, Makielski JC, Towbin JA. Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA. 2001;286:2264–9. [PubMed: 11710892]
  4. Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol. 2004;2004;15:72–6. [PubMed: 15028076]
  5. Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Wang DW, Rhodes TE, George AL Jr, Schwartz PJ. Prevalence of long-QT syndrome gene variants in sudden infant death syndrome. Circulation. 2007;115:361–7. [PubMed: 17210839]
  6. Barc J, Briec F, Schmitt S, Kyndt F, Le Cunff M, Baron E, Vieyres C, Sacher F, Redon R, Le Caignec C, Le Marec H, Probst V, Schott JJ. Screening for copy number variation in genes associated with the long QT syndrome: clinical relevance. J Am Coll Cardiol. 2011;57:40–7. [PubMed: 21185499]
  7. Cronk LB, Ye B, Kaku T, Tester DJ, Vatta M, Makielski JC, Ackerman MJ. Novel mechanism for sudden infant death syndrome: persistent late sodium current secondary to mutations in caveolin-3. Heart Rhythm. 2007;4:161–6. [PMC free article: PMC2836535] [PubMed: 17275750]
  8. Goldenberg I, Horr S, Moss AJ, Lopes CM, Barsheshet A, McNitt S, Zareba W, Andrews ML, Robinson JL, Locati EH, Ackerman MJ, Benhorin J, Kaufman ES, Napolitano C, Platonov PG, Priori SG, Qi M, Schwartz PJ, Shimizu W, Towbin JA, Vincent GM, Wilde AA, Zhang L. Risk for life-threatening cardiac events in patients with genotype-confirmed long-QT syndrome and normal-range corrected QT intervals. J Am Coll Cardiol. 2011;57:51–9. [PMC free article: PMC3332533] [PubMed: 21185501]
  9. Goldenberg I, Zareba W, Moss AJ, Long QT. Syndrome. Curr Probl Cardiol. 2008;33:629–94. [PubMed: 18835466]
  10. Horner JM, Horner MM., Ackermann MJ. The diagnostic utility of recovery phase QTc during treadmill exercise stress testing in the evaluation of long QT syndrome. Heart Rhythm. 2011;8:1698–704. [PubMed: 21699858]
  11. Itoh H, Shimizu W, Hayashi K, Yamagata K, Sakaguchi T, Ohno S, Makiyama T, Akao M, Ai T, Noda T, Miyazaki A, Miyamoto Y, Yamagishi M, Kamakura S, Horie M. Long QT syndrome with compound mutations is associated with a more severe phenotype: a Japanese multicenter study. Heart Rhythm. 2010;7:1411–8. [PubMed: 20541041]
  12. Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54:59–68. [PubMed: 13435203]
  13. Johnson JN, Ackerman MJ. Competitive sports participation in athletes with congenital long QT syndrome. JAMA. 2012;308:764–5. [PubMed: 22820673]
  14. Jons C, Moss AJ, Goldenberg I, Liu J, McNitt S, Zareba W, Qi M, Robinson JL. Risk of fatal arrhythmic events in long QT syndrome patients after syncope. J Am Coll Cardiol. 2010;55:783–8. [PubMed: 20170817]
  15. Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, Wilde AA, Ackerman MJ. Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants. Circulation. 2009;120:1752–60. [PMC free article: PMC3025752] [PubMed: 19841300]
  16. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, Ackerman MJ. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009;6:1297–303. [PMC free article: PMC3049907] [PubMed: 19716085]
  17. Kaufman ES, McNitt S, Moss AJ, Zareba W, Robinson JL, Hall WJ, Ackerman MJ, Benhorin J, Locati ET, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L. Risk of death in the long QT syndrome when a sibling has died. Heart Rhythm. 2008;5:831–6. [PMC free article: PMC2486317] [PubMed: 18534367]
  18. Keating MT, Sanguinetti MC. Molecular and cellular mechanisms of cardiac arrhythmias. Cell. 2001;104:569–80. [PubMed: 11239413]
  19. Locati EH, Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Lehmann MH, Towbin JA, Priori SG, Napolitano C, Robinson JL, Andrews M, Timothy K, Hall WJ. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: findings from the International LQTS Registry. Circulation. 1998;97:2237–44. [PubMed: 9631873]
  20. Mohler PJ, Le Scouarnec S, Denjoy I, Lowe JS, Guicheney P, Caron L, Driskell IM, Schott JJ, Norris K, Leenhardt A, Kim RB, Escande D, Roden DM. Defining the cellular phenotype of "ankyrin-B syndrome" variants: human ANK2 variants associated with clinical phenotypes display a spectrum of activities in cardiomyocytes. Circulation. 2007;115:432–41. [PubMed: 17242276]
  21. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH, Song LS, Haurogne K, Kyndt F, Ali ME, Rogers TB, Lederer WJ, Escande D, Le Marec H, Bennett V. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature. 2003;421:634–9. [PubMed: 12571597]
  22. Moss AJ, Windle JR, Hall WJ, Zareba W, Robinson JL, McNitt S, Severski P, Rosero S, Daubert JP, Qi M, Cieciorka M, Manalan AS. Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol. 2005;10:59–66. [PubMed: 16274417]
  23. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J, Vincent GM, Locati EH, Priori SG, Napolitano C, Medina A, Zhang L, Robinson JL, Timothy K, Towbin JA, Andrews ML. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation. 2000;101:616–23. [PubMed: 10673253]
  24. Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008;19:1289–93. [PMC free article: PMC2614458] [PubMed: 18662191]
  25. Nannenberg EA, Sijbrands EJ, Dijksman LM, Alders M, van Tintelen JP, Birnie M, Van Langen IM, Wilde AA. Mortality of inherited arrhythmia syndromes: insight into their natural history. Circ Cardiovasc Genet. 2012;5:183–9. [PubMed: 22373669]
  26. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, Leonardi S. Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice. JAMA. 2005;294:2975–80. [PubMed: 16414944]
  27. Priori SG, Napolitano C, Schwartz PJ, Grillo M, Bloise R, Ronchetti E, Moncalvo C, Tulipani C, Veia A, Bottelli G, Nastoli J. Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers. JAMA. 2004;292:1341–4. [PubMed: 15367556]
  28. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, Vicentini A, Spazzolini C, Nastoli J, Bottelli G, Folli R, Cappelletti D. Risk stratification in the long-QT syndrome. N Engl J Med. 2003;348:1866–74. [PubMed: 12736279]
  29. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu W, Tomaselli G, Tracy C. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932–63. [PubMed: 24011539]
  30. Schwartz PJ, Crotti L. QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation. 2011;124:2181–4. [PubMed: 22083145]
  31. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation. 1993;88:782–4. [PubMed: 8339437]
  32. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, Bloise R, De Ferrari GM, Klersy C, Moss AJ, Zareba W, Robinson JL, Hall WJ, Brink PA, Toivonen L, Epstein AE, Li C, Hu D. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation. 2004;109:1826–33. [PubMed: 15051644]
  33. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantù F, Towbin JA, Keating MT, Hammoude H, Brown AM, Chen LS. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995;92:3381–6. [PubMed: 8521555]
  34. Schwartz PJ, Priori SG, Napolitano C. How really rare are rare diseases? J Cardiovasc Electrophysiol. 2003;14:1120–1. [PubMed: 14521668]
  35. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I, Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA, Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation. 2001;103:89–95. [PubMed: 11136691]
  36. Schwartz PJ, Spazzolini C, Crotti L. All LQT3 patients need an ICD: true or false? Heart Rhythm. 2009;6:113–20. [PubMed: 19121811]
  37. Seth R, Moss AJ, McNitt S, Zareba W, Andrews ML, Qi M, Robinson JL, Goldenberg I, Ackerman MJ, Benhorin J, Kaufman ES, Locati EH, Napolitano C, Priori SG, Schwartz PJ, Towbin JA, Vincent GM, Zhang L. Long QT syndrome and pregnancy. J Am Coll Cardiol. 2007;49:1092–8. [PubMed: 17349890]
  38. Shimizu W, Noda T, Takaki H, Nagaya N, Satomi K, Kurita T, Suyama K, Aihara N, Sunagawa K, Echigo S, Miyamoto Y, Yoshimasa Y, Nakamura K, Ohe T, Towbin JA, Priori SG, Kamakura S. Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm. 2004;1:276–83. [PubMed: 15851169]
  39. Spazzolini C, Mullally J, Moss AJ, Schwartz PJ, McNitt S, Ouellet G, Fugate T, Goldenberg I, Jons C, Zareba W, Robinson JL, Ackerman MJ, Benhorin J, Crotti L, Kaufman ES, Locati EH, Qi M, Napolitano C, Priori SG, Towbin JA, Vincent GM. Clinical implications for patients with long QT syndrome who experience a cardiac event during infancy. J Am Coll Cardiol. 2009;54:832–7. [PMC free article: PMC3517782] [PubMed: 19695463]
  40. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation. 2000;102:1178–85. [PubMed: 10973849]
  41. Swan H, Toivonen L, Viitasalo M. Rate adaptation of QT intervals during and after exercise in children with congenital long QT syndrome. Eur Heart J. 1998;19:508–13. [PubMed: 9568456]
  42. Sy RW, van der Werf C, Chattha IS, Chockalingam P, Adler A, Healey JS, Perrin M, Gollob MH, Skanes AC, Yee R, Gula LJ, Leong-Sit P, Viskin S, Klein GJ, Wilde AA, Krahn AD. Derivation and validation of a simple exercise-based algorithm for prediction of genetic testing in relatives of LQTS probands. Circulation. 2011;124:2187–94. [PubMed: 22042885]
  43. Tester DJ, Will ML, Haglund CM, Ackerman MJ. Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing. Heart Rhythm. 2005;2:507–17. [PubMed: 15840476]
  44. Van Langen IM, Birnie E, Alders M, Jongbloed RJ, Le Marec H, Wilde AA. The use of genotype-phenotype correlations in mutation analysis for the long QT syndrome. J Med Genet. 2003;40:141–5. [PMC free article: PMC1735373] [PubMed: 12566525]
  45. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, Taylor EW, Tester DJ, Balijepalli RC, Foell JD, Li Z, Kamp TJ, Towbin JA. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation. 2006;114:2104–12. [PubMed: 17060380]
  46. Vincent GM, Jaiswal D, Timothy KW. Effects of exercise on heart rate, QT, QTc and QT/QS2 in the Romano-Ward inherited long QT syndrome. Am J Cardiol. 1991;68:498–503. [PubMed: 1872278]
  47. Vincent GM, Schwartz PJ, Denjoy I, Swan H, Bithell C, Spazzolini C, Crotti L, Piippo K, Lupoglazoff JM, Villain E, Priori SG, Napolitano C, Zhang L. High efficacy of beta-blockers in long-QT syndrome type1; contribution of noncompliance and QT-prolonging drugs to the occurrence of beta-blocker treatment “failures”. Circulation. 2009;119:215–21. [PubMed: 19118258]
  48. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med. 1992;327:846–52. [PubMed: 1508244]
  49. Viskin S, Postema PG, Bhuiyan ZA, Rosso R, Kalman JM, Vohra JK, Guevara-Valdivia ME, Marquez MF, Kogan E, Belhassen B, Glikson M, Strasberg B, Antzelevitch C, Wilde AAM. The response of the QT interval to the brief tachycardia provoked by standing a bedside test for diagnosing long QT syndrome. JACC. 2010;55:1955–61. [PMC free article: PMC2862092] [PubMed: 20116193]
  50. Vyas H, Hejlik J, Ackerman MJ. Epinephrine QT stress testing in the evaluation of congenital long-QT syndrome: diagnostic accuracy of the paradoxical QT response. Circulation. 2006;113:1385–92. [PubMed: 16534005]
  51. Wedekind H, Bajanowski T, Friederich P, Breithardt G, Wülfing T, Siebrands C, Engeland B, Mönnig G, Haverkamp W, Brinkmann B, Schulze-Bahr E. Sudden infant death syndrome and long QT syndrome: an epidemiological and genetic study. Int J Legal Med. 2006;120:129–37. [PubMed: 16012827]
  52. Westenskow P, Splawski I, Timothy KW, Keating MT, Sanguinetti MC. Compound mutations: a common cause of severe long-QT syndrome. Circulation. 2004;109:1834–41. [PubMed: 15051636]
  53. Zareba W, Moss AJ, Daubert JP, Hall WJ, Robinson JL, Andrews M. Implantable cardioverter defibrillator in high-risk long QT syndrome patients. J Cardiovasc Electrophysiol. 2003;14:337–41. [PubMed: 12741701]
  54. Zareba W, Moss AJ, Schwartz PJ, Vincent GM, Robinson JL, Priori SG, Benhorin J, Locati EH, Towbin JA, Keating MT, Lehmann MH, Hall WJ. Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med. 1998;339:960–5. [PubMed: 9753711]
  55. Zhang L, Timothy KW, Vincent GM, Lehmann MH, Fox J, Giuli LC, Shen J, Splawski I, Priori SG, Compton SJ, Yanowitz F, Benhorin J, Moss AJ, Schwartz PJ, Robinson JL, Wang Q, Zareba W, Keating MT, Towbin JA, Napolitano C, Medina A. Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation. 2000;102:2849–55. [PubMed: 11104743]

Chapter Notes

Author History

Mariëlle Alders, PhD (2012-present)
Imke Christiaans, PhD, MD (2015-present)
Marcel MAM Mannens, PhD; University of Amsterdam (2012-2015)
G Michael Vincent, MD; University of Utah School of Medicine (2003-2012)

Revision History

  • 18 June 2015 (me) Comprehensive update posted live (title change)
  • 31 May 2012 (me) Comprehensive update posted live
  • 4 August 2009 (cd) Revision: prenatal diagnosis available for LQT1, LQT2, LQT3, LQT5, LQT6
  • 7 May 2009 (gmv) Revision: deletion/duplication analysis available clinically for LQT2 and LQT3; additions to Management
  • 21 May 2008 (me) Comprehensive update posted live
  • 7 July 2005 (me) Comprehensive update posted to live Web site
  • 28 February 2005 (gmv) Revision: sequence analysis clinically available; LQt4 moved to Differential Diagnosis
  • 13 April 2004 (cd) Revision: ANK2 testing clinically available
  • 11 February 2004 (bp/gmv) Revisions
  • 18 November 2003 (gmv) Revisions
  • 16 June 2003 (gmv) Revision: Table 4
  • 20 February 2003 (me) Review posted to live Web site
  • 25 October 2002 (gmv) Original submission
Copyright © 1993-2016, University of Washington, Seattle. All rights reserved.

For more information, see the GeneReviews Copyright Notice and Usage Disclaimer.

For questions regarding permissions: ude.wu@tssamda.

Bookshelf ID: NBK1129PMID: 20301308

Views

Related information

  • MedGen
    Related information in MedGen
  • OMIM
    Related OMIM records
  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed
  • Gene
    Locus Links

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...